Current Hematologic Malignancy Reports

Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the diagnosis, treatment, management, and prevention of conditions associated with hematologic malignancy.This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

目前的血液学恶性肿瘤报告提供了国际专家对该领域最重要进展的深入评论文章。通过发表清晰、有见地、平衡的评论，强调最近发表的重要论文，该杂志阐明了当前和新出现的诊断、治疗、管理和预防血液恶性肿瘤相关疾病的方法。本杂志旨在提供国际专家清晰、有见地、平衡的贡献，这些专家回顾了最近发表的与血液学恶性肿瘤的诊断、治疗、管理和预防有关的最重要的临床发现。我们通过任命国际权威机构担任关键学科领域（如白血病、淋巴瘤、骨髓瘤、T细胞和其他淋巴增生性恶性肿瘤）的部门编辑来实现这一目标。章节编辑依次选择主要专家撰写综合性评论文章的主题，强调新的发展和最近出版的重要论文，并以注释参考列表突出。一个国际编辑委员会审查年度目录，向其国家/地区推荐特别感兴趣的文章，并确保主题是最新的，包括新的研究。还提供了该领域知名人士的评论。